Stan Berenshteyn
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
53
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMCL Omnicell | Maintains: Equal-Weight | $30 → $41 | $48.67 | -15.76% | 11 | Oct 14, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $7 → $6 | $3.20 | +87.50% | 10 | Oct 11, 2024 | |
| AMWL American Well | Maintains: Equal-Weight | $40 → $15 | $9.00 | +66.67% | 2 | Aug 6, 2024 | |
| DOCS Doximity | Downgrades: Underweight | $27 → $19 | $42.35 | -55.14% | 7 | Jul 18, 2024 | |
| HQY HealthEquity | Maintains: Overweight | $107 → $110 | $86.33 | +27.42% | 8 | Jun 20, 2024 | |
| HCAT Health Catalyst | Maintains: Overweight | $14 → $13 | $7.70 | +68.83% | 4 | May 10, 2024 | |
| GDRX GoodRx Holdings | Upgrades: Overweight | $10 | $6.19 | +61.55% | 6 | Mar 25, 2024 | |
| VEEV Veeva Systems | Upgrades: Overweight | $211 → $229 | $212.78 | +7.62% | 3 | Oct 25, 2023 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $28 → $23 | $9.21 | +149.73% | 2 | Mar 6, 2023 |
Omnicell
Oct 14, 2024
Maintains: Equal-Weight
Price Target: $30 → $41
Current: $48.67
Upside: -15.76%
Accolade
Oct 11, 2024
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.20
Upside: +87.50%
American Well
Aug 6, 2024
Maintains: Equal-Weight
Price Target: $40 → $15
Current: $9.00
Upside: +66.67%
Doximity
Jul 18, 2024
Downgrades: Underweight
Price Target: $27 → $19
Current: $42.35
Upside: -55.14%
HealthEquity
Jun 20, 2024
Maintains: Overweight
Price Target: $107 → $110
Current: $86.33
Upside: +27.42%
Health Catalyst
May 10, 2024
Maintains: Overweight
Price Target: $14 → $13
Current: $7.70
Upside: +68.83%
GoodRx Holdings
Mar 25, 2024
Upgrades: Overweight
Price Target: $10
Current: $6.19
Upside: +61.55%
Veeva Systems
Oct 25, 2023
Upgrades: Overweight
Price Target: $211 → $229
Current: $212.78
Upside: +7.62%
Teladoc Health
Mar 6, 2023
Maintains: Equal-Weight
Price Target: $28 → $23
Current: $9.21
Upside: +149.73%